Indeed, the inhibition of glucagon release by GLP-1 is believed to contribute to the clinical effectiveness of GLP-1 mimetics for the treatment of Type 2 diabetes, as the hyperglucagonaemia commonly seen in diabetes is partially responsible for the raised glucose levels. Here, GCG is linked to type 2 diabetes mellitus.